Poor
Not Aligned
Patient Risk:
Moderate
Summary
Many specific interaction/avoidance and symptom-response instructions (notably for St. John’s wort and red yeast rice) are not supported by the supplied Lipitor FDA label excerpts. Only general statin liver-enzyme and skeletal-muscle risk concepts and CYP3A4 strong-inhibitor interaction effects are partially supported.
Category Scores
Accurate Statements
Supplements that meaningfully inhibit CYP3A4 or P-glycoprotein can increase atorvastatin levels.
Partially supported: label states LIPITOR is metabolized by CYP3A4 and strong CYP3A4 inhibitors can increase atorvastatin plasma concentrations (7.1 Strong Inhibitors of CYP 3A4). P-glycoprotein component not supported by provided excerpts.
Supplements that increase atorvastatin levels can raise the risk of muscle side effects.
Supported: label indicates increased atorvastatin concentrations with strong CYP3A4 inhibitors and increased risk of myopathy/rhabdomyolysis (5.1 Skeletal Muscle; 7.1).
Statins can raise liver enzymes in some people.
Supported: label notes biochemical abnormalities of liver function, including persistent elevations in serum transaminases (5.2 Liver Dysfunction).
Unsupported Statements
St. John’s wort can reduce blood levels of many medicines by changing drug metabolism and transport.
No support in the provided label excerpts.
St. John’s wort can make Lipitor (atorvastatin) work less effectively.
No support in the provided label excerpts.
Avoid using St. John’s wort with Lipitor unless a clinician specifically approves.
No support in the provided label excerpts.
Red yeast rice contains naturally occurring statin-like compounds (monacolin K).
No support in the provided label excerpts.
Taking red yeast rice with Lipitor can effectively double up on statin exposure.
No support in the provided label excerpts.
Taking red yeast rice with Lipitor increases the risk of muscle injury.
No support in the provided label excerpts.
Taking red yeast rice with Lipitor increases the risk of liver enzyme elevations.
No support in the provided label excerpts.
Concentrated herbal extracts may have interaction potential, especially when doses are high or products are poorly standardized.
No support in the provided label excerpts.
If a supplement label does not clearly show exact ingredients and dosing, it is harder to predict interaction risk.
No support in the provided label excerpts.
Pairing Lipitor with supplements known or suspected to stress the liver can increase the chance of liver-related side effects.
No support in the provided label excerpts.
In general, standard doses of common vitamins and minerals are usually safe for many people on statins.
No support in the provided label excerpts.
Very high doses of supplements (especially certain compounds) can add risk factors when taking Lipitor.
No support in the provided label excerpts.
Products that include enzyme-inhibiting herbs can add risk factors when taking Lipitor.
No support in the provided label excerpts.
Products that include additional statin-like ingredients (like red yeast rice) can add risk factors when taking Lipitor.
No support in the provided label excerpts.
Supplements used as 'muscle-building' or 'fat-burning' blends may contain undisclosed or concentrated herbal extracts.
No support in the provided label excerpts.
Supplements used as 'muscle-building' or 'fat-burning' blends may add risk factors when taking Lipitor.
No support in the provided label excerpts.
Some products sold as dietary supplements act like drugs.
No support in the provided label excerpts.
Red yeast rice is one of the supplements most commonly flagged to avoid with prescription statins like Lipitor because it contains statin-like medication.
No support in the provided label excerpts.
If a person takes Lipitor and uses any supplement that may interact, they should stop the supplement and contact a clinician promptly if new muscle pain, tenderness, weakness, or cramps develop.
Partially supported at most: label advises reporting unexplained muscle pain/tenderness/weakness and discontinuing LIPITOR if myopathy/myopathy suspected, but provided excerpts do not instruct stopping the supplement or reference 'any supplement.' (5.1)
New muscle pain, tenderness, weakness, or cramps on Lipitor are especially concerning if severe or widespread.
No support in the provided label excerpts.
If a person takes Lipitor and uses any interacting supplement, they should stop the supplement and contact a clinician promptly if they develop dark/tea-colored urine.
No support in the provided label excerpts.
If a person takes Lipitor and uses any interacting supplement, they should stop the supplement and contact a clinician promptly if they develop unusual fatigue or flu-like symptoms.
No support in the provided label excerpts.
If a person takes Lipitor and uses any interacting supplement, they should stop the supplement and contact a clinician promptly if they develop yellowing of skin/eyes or severe nausea.
No support in the provided label excerpts.
Yellowing of skin/eyes or severe nausea while using Lipitor with an interacting supplement may indicate possible liver issues.
No support in the provided label excerpts.
If an interacting supplement was a one-time dose and the patient feels well, the immediate risk may be low.
No support in the provided label excerpts.
Even if an interacting supplement was a one-time dose, the patient should still tell the prescriber or pharmacist and ask whether to stop the product.
No support in the provided label excerpts.
If a patient has muscle symptoms or dark urine after taking an interacting supplement with Lipitor, they should seek urgent medical advice.
No support in the provided label excerpts.
Red yeast rice should be avoided with Lipitor.
No support in the provided label excerpts.
St. John’s wort should be avoided with Lipitor.
No support in the provided label excerpts.
Contradictions
Important Omissions
Label-supported, specific interaction examples and prescribing recommendations are limited to strong CYP3A4 inhibitors and certain other drug classes in the provided excerpts (e.g., clarithromycin/itraconazole/HIV protease inhibitors/cyclosporine/fibric acid derivatives/niacin). The response makes broad supplement-class claims without aligning to these provided label categories.
Importance:
Moderate
The supplied excerpts do not provide label-supported symptom-specific pairings for dark urine/flu-like symptoms/severe nausea or 'stop the supplement' workflows; the response includes these without label support.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes multiple high-specificity avoidance and safety-action recommendations for St. John’s wort and red yeast rice that are not supported by the provided Lipitor label excerpts, plus several symptom-triggered instructions without label backing. While it does align with some general statin skeletal muscle and liver-enzyme risk concepts, the unsupported directives could mislead clinical decision-making.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most specific supplement interaction/avoidance and symptom-response recommendations (St. John’s wort, red yeast rice, and multiple symptom triggers) are absent from the provided FDA label excerpts; only general statin liver enzyme and skeletal muscle monitoring/risk and strong CYP3A4 inhibitor interaction concepts are partially supported.
Suggested Improvement
Restrict interaction statements to label-supported categories in the provided excerpts (e.g., strong CYP3A4 inhibitors increasing atorvastatin concentrations; increased myopathy/rhabdomyolysis risk with certain interacting drugs; LFT monitoring). Remove or rephrase St. John’s wort/red yeast rice-specific avoidance and the symptom-triggered 'stop the supplement/urgent' instructions unless supported by additional label sections not provided here.